JIB‑04 induces cell apoptosis via activation of the p53/Bcl‑2/caspase pathway in MHCC97H and HepG2 cells

Liao,Weiguo; Liu,Jie; Liu,Bin; Huang,Xiaojie; Yin,Yongxin; Cai,De; Li,Mingyi; Zhu,Runzhi

doi:10.3892/or.2018.6737

JIB‑04 induces cell apoptosis via activation of the p53/Bcl‑2/caspase pathway in MHCC97H and HepG2 cells

Authors:
- Weiguo Liao
- Jie Liu
- Bin Liu
- Xiaojie Huang
- Yongxin Yin
- De Cai
- Mingyi Li
- Runzhi Zhu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China, Department of Hepatobiliary Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China, Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China
Published online on: September 26, 2018 https://doi.org/10.3892/or.2018.6737
Pages: 3812-3820

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

JIB‑04 is a structurally unique small molecule, known to exhibit anticancer activity and to inhibit the growth of human lung cancer and prostate cancer cell lines. However, the anticancer effect of JIB‑04 against human hepatic carcinoma, and its underlying mechanisms, are still unclear. In the present study, MHCC97H and HepG2 cells were employed to investigate the anticancer effects of JIB‑04 on cell viability and apoptosis. Annexin V/PI staining, a CCK‑8 assay and western blot analysis demonstrated that JIB‑04 induced apoptosis in MHCC97H and HepG2 cells, which was evidenced by the expression of proapoptotic and apoptotic proteins including p53, Bak, Bax, caspase‑3 and caspase‑9. Subsequently, the expression trends of Bcl‑2 and p53 were reversed after co‑treatment with pifithrin‑α (PFT‑α, a p53 inhibitor). The results revealed that JIB‑04 suppressed the cell viability of MHCC97H and HepG2 cells in a concentration‑dependent manner. Meanwhile, it was also demonstrated that JIB‑04 effectively triggered MHCC97H and HepG2 cell apoptosis by downregulating Bcl‑2/Bax expression, and upregulating proapoptotic and apoptotic protein expression via the p53/Bcl2/caspase signaling pathway. JIB‑04 had effects on the inhibition of cell viability and the induction of apoptosis in MHCC97H and HepG2 cells. The underlying mechanism of action of JIB‑04 was associated with the p53/Bcl‑2/caspase signaling pathway. Our findings provide a foundation for understanding the anticancer effect of JIB‑04 on MHCC97H and HepG2 cells, and suggested that JIB‑04 may be a promising therapeutic agent in human liver cancer.

View Figures

View References

1	Cheng JS, Chou CT, Liu YY, Sun WC, Shieh P, Kuo DH, Kuo CC, Jan CR and Liang WZ: The effect of oleuropein from olive leaf (Olea europaea) extract on Ca²⁺ homeostasis, cytotoxicity, cell cycle distribution and ROS signaling in HepG2 human hepatoma cells. Food Chem Toxicol. 91:151–166. 2016. View Article : Google Scholar : PubMed/NCBI
2	Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS and Ho M: Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA. 110:E1083–E1091. 2013. View Article : Google Scholar : PubMed/NCBI
3	Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
4	Zhang Q, Ma S, Liu B, Liu J, Zhu R and Li M: Chrysin induces cell apoptosis via activation of the p53/Bcl-2/caspase-9 pathway in hepatocellular carcinoma cells. Exp Ther Med. 12:469–474. 2016. View Article : Google Scholar : PubMed/NCBI
5	Au JS and Frenette CT: Management of hepatocellular carcinoma: Current status and future directions. Gut Liver. 9:437–448. 2015. View Article : Google Scholar : PubMed/NCBI
6	Bruix J, Gores GJ and Mazzaferro V: Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
7	Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, Wang H, Yang Y, et al: Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett. 383:171–182. 2016. View Article : Google Scholar : PubMed/NCBI
8	Luo HL, Chen J, Luo T, Wu FX, Liu JJ, Wang HF, Chen M, Li LQ and Li H: Downregulation of macrophage-derived T-UCR uc.306 associates with poor prognosis in hepatocellular carcinoma. Cell Physiol Biochem. 42:1526–1539. 2017. View Article : Google Scholar : PubMed/NCBI
9	Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, et al: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16:1344–1354. 2015. View Article : Google Scholar : PubMed/NCBI
10	Horgan AM, Dawson LA, Swaminath A and Knox JJ: Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. J Gastrointest Cancer. 43:344–348. 2012. View Article : Google Scholar : PubMed/NCBI
11	Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, et al: Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: The RESPECT trial. Clin Cancer Res. 19:2541–2550. 2013. View Article : Google Scholar : PubMed/NCBI
12	López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar
13	Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, Ruiz J, Bruick R, Peña-Llopis S, Xu J, et al: A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun. 4:20352013. View Article : Google Scholar : PubMed/NCBI
14	Olivier M, Hollstein M and Hainaut P: TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
15	Osborne C, Wilson P and Tripathy D: Oncogenes and tumor suppressor genes in breast cancer: Potential diagnostic and therapeutic applications. Oncologist. 9:361–377. 2004. View Article : Google Scholar : PubMed/NCBI
16	Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al: Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 148:244–258. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bailey SM, Meyne J, Chen DJ, Kurimasa A, Li GC, Lehnert BE and Goodwin EH: DNA double-strand break repair proteins are required to cap the ends of mammalian chromosomes. Proc Natl Acad Sci USA. 96:14899–14904. 1999. View Article : Google Scholar : PubMed/NCBI
18	Vazquez A, Bond EE, Levine AJ and Bond GL: The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 7:979–987. 2008. View Article : Google Scholar : PubMed/NCBI
19	Degenhardt K, Chen G, Lindsten T and White E: BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell. 2:193–203. 2002. View Article : Google Scholar : PubMed/NCBI
20	Henry H, Thomas A, Shen Y and White E: Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene. 21:748–760. 2002. View Article : Google Scholar : PubMed/NCBI
21	Mauer K, O'Kelley R, Poddar N, Flanagan S and Gadani S: Erratum to: New treatment modalities for hepatocellular cancer. Curr Gastroenterol Rep. 17:492015. View Article : Google Scholar : PubMed/NCBI
22	Wang Y, Deng T, Zeng L and Chen W: Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. Hepatol Res. 46:58–71. 2016. View Article : Google Scholar : PubMed/NCBI
23	Ding G, Peng Z, Shang J, Kang Y, Ning H and Mao C: LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through miR-9/E-cadherin cascade signaling pathway molecular mechanism. Onco Targets Ther. 10:3241–3247. 2017. View Article : Google Scholar : PubMed/NCBI
24	Alenzi FQ, Alenazi BQ, Al-Anazy FH, Mubaraki AM, Salem ML, Al-Jabri AA, Lotfy M, Bamaga MS, Alrabia MW and Wyse RK: The role of caspase activation and mitochondrial depolarisation in cultured human apoptotic eosinophils. Saudi J Biol Sci. 17:29–36. 2010. View Article : Google Scholar : PubMed/NCBI
25	Wu S, Liu B, Zhang Q, Liu J, Zhou W, Wang C, Li M, Bao S and Zhu R: Dihydromyricetin reduced Bcl-2 expression via p53 in human hepatoma HepG2 cells. PLoS One. 8:e768862013. View Article : Google Scholar : PubMed/NCBI
26	Powell CB, Fung P, Jackson J, Dal l'Era J, Lewkowicz D, Cohen I and Smith-McCune K: Aqueous extract of herba Scutellaria barbatae, a chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines. Gynecol Oncol. 91:332–340. 2003. View Article : Google Scholar : PubMed/NCBI
27	Yuan CH, Filippova M and Duerksen-Hughes P: Modulation of apoptotic pathways by human papillomaviruses (HPV): Mechanisms and implications for therapy. Viruses. 4:3831–3850. 2012. View Article : Google Scholar : PubMed/NCBI
28	McIlwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
29	Poku RA, Salako OO, Amissah F, Nkembo AT, Ntantie E and Lamango NS: Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. Am J Cancer Res. 7:1515–1527. 2017.PubMed/NCBI
30	Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK: Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
31	Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S and Dent P: PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther. 14:458–465. 2013. View Article : Google Scholar : PubMed/NCBI
32	Ciccarone F, Klinger FG, Catizone A, Calabrese R, Zampieri M, Bacalini MG, De Felici M and Caiafa P: Poly(ADP-ribosyl)ation acts in the DNA demethylation of mouse primordial germ cells also with DNA damage-independent roles. PLoS One. 7:e469272012. View Article : Google Scholar : PubMed/NCBI
33	Zhang Q, Liu J, Liu B, Xia J, Chen N, Chen X, Cao Y, Zhang C, Lu C, Li M, et al: Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism. Sci Rep. 4:46282014. View Article : Google Scholar : PubMed/NCBI
34	Reed JC: Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 34 4 Suppl 5:S9–S19. 1997.
35	Pettersson F, Dalgleish AG, Bissonnette RP and Colston KW: Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer. 87:555–561. 2002. View Article : Google Scholar : PubMed/NCBI
36	Peña-Blanco A and García-Sáez AJ: Bax, Bak and beyond-mitochondrial performance in apoptosis. FEBS J. 285:416–431. 2018. View Article : Google Scholar : PubMed/NCBI
37	Carr MI and Jones SN: Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. Transl Cancer Res. 5:707–724. 2016. View Article : Google Scholar : PubMed/NCBI
38	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI
39	Minsky N and Oren M: The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell. 16:631–639. 2004. View Article : Google Scholar : PubMed/NCBI
40	Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997. View Article : Google Scholar : PubMed/NCBI
41	Mu R, Lu N, Wang J, Yin Y, Ding Y, Zhang X, Gui H, Sun Q, Duan H, Zhang L, et al: An oxidative analogue of gambogic acid-induced apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its anticancer activity in vitro. Eur J Cancer Prev. 19:61–67. 2010. View Article : Google Scholar : PubMed/NCBI
42	Papazoglu C and Mills AA: p53: At the crossroad between cancer and ageing. J Pathol. 211:124–133. 2007. View Article : Google Scholar : PubMed/NCBI